Back to top
more

Bruker (BRKR)

(Real Time Quote from BATS)

$63.22 USD

63.22
924,959

-2.66 (-4.04%)

Updated Aug 5, 2024 03:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (103 out of 251)

Industry: Instruments - Scientific

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Bruker To Buy Freiberg Instruments' Magnettech EPR Business

by Zacks Equity Research

The Freiberg Instruments' Magnettech EPR business acquisition is expected to boost Bruker's (BRKR) BioSpin business by complementing its existing range of EPR offerings.

Bruker (BRKR) Enters Into Alliance With Murdoch University

by Zacks Equity Research

Bruker's (BRKR) collaboration with Murdoch University will support International Centre of Excellence in metabolic phenotyping.

Bruker (BRKR) Introduces the nanoIR3-s Broadband System

by Zacks Equity Research

The launch of the FTIR spectroscopy system complements Bruker's (BRKR) target to boost its portfolio of nanoIR products.

Bruker (BRKR) Releases JPK NanoWizard 4 XP Bio-AFM System

by Zacks Equity Research

With the launch of this new system, Bruker (BRKR) establishes a performance yardstick for atomic force microscopy in the field of life science research.

Bruker (BRKR) Down 7.4% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Bruker (BRKR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Bruker (BRKR) Q2 Earnings Beat Estimates, Margins Expand

by Zacks Equity Research

Bruker (BRKR) registers strong year-over-year revenue growth across all segments and geographies.

Bruker (BRKR) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Bruker (BRKR) delivered earnings and revenue surprises of 6.45% and 2.71%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Garmin's (GRMN) Q2 Earnings & Revenues Surpass Estimates

by Zacks Equity Research

Garmin's (GRMN) second-quarter results benefit from strong performance by its fitness, outdoor, marine and aviation segments.

Can Bruker (BRKR) Q2 Earnings See BioSpin's Growth Revival?

by Zacks Equity Research

Bruker (BRKR) expects BioSpin to bode well for better organic growth in Q2.

Is Bruker (BRKR) Outperforming Other Computer and Technology Stocks This Year?

by Zacks Equity Research

Is (BRKR) Outperforming Other Computer and Technology Stocks This Year?

Bruker (BRKR) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Bruker (BRKR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Illumina (ILMN) Grows on Innovation & International Growth

by Zacks Equity Research

Illumina (ILMN) is benefiting from sturdy demand for sequencing and array systems as well as consumables and services.

NuVasive (NUVA) Launches Pulse Integrated Technology Platform

by Zacks Equity Research

The launch of this system is in sync with NuVasive's (NUVA) endeavor to deliver end-to-end solutions that offer predictable clinical and economic outcomes in spine surgery.

Boston Scientific's Global Growth Robust Amid Currency Woe

by Zacks Equity Research

Boston Scientific (BSX) is currently pinning hopes on a stronger performance in China, backed by the recent approval of SYNERGY in the country.

Has Bruker (BRKR) Outpaced Other Computer and Technology Stocks This Year?

by Zacks Equity Research

Is (BRKR) Outperforming Other Computer and Technology Stocks This Year?

Medtronic Releases Positive Results of LATERAL Clinical Trial

by Zacks Equity Research

Positive outcomes prove to be a major breakthrough for Medtronic (MDT) in the growing field of ventricular assist devices.

ResMed (RMD) Rides on Strong SaaS Growth & New Product Suite

by Zacks Equity Research

ResMed's (RMD) new product menu and an array of strategies are likely to benefit from the sleep-disordered breathing market. This should further drive its short-term performance.

Integra Partners AI-Driven Data Analytics Firm in Wound Care

by Zacks Equity Research

Integra LifeSciences (IART) expects its partnership with Tissue Analytics to be perfectly strategic as the latter's software solutions automatically derive high quality data from clinical pictures.

Phibro Animal Sees Crucial Progress in ASF Vaccine Development

by Zacks Equity Research

The identification of a group of peptides and proteins is a remarkable step toward Phibro's (PAHC) development of a solution for ASF.

Fresenius Set for Global Expansion of Research Activities

by Zacks Equity Research

Fresenius Medical Care (FMS) aims to expand the scope of its clinical research activities through an integration move.

Illumina (ILMN) Hits 52-Week High, Can the Run Continue?

by Zacks Equity Research

Illumina (ILMN) gains from expansion of its product portfolio and strategic partnership.

CVS Health Banks on Aetna Prospects, Omnicare May Disappoint

by Zacks Equity Research

CVS Health's (CVS) Aetna integration synergies bode well for the stock.

Boston Scientific to Sell Bead Suit, Make Way for BTG Buyout

by Zacks Equity Research

The sale of oncology bead products by Boston Scientific (BSX) is expected to be among the last steps undertaken by the company to obtain Federal Trade Commission's approval for BTG buyout.

Here's Why CVS Health (CVS) Should Be in Your Portfolio

by Zacks Equity Research

Investors' trust continues to be high in CVS Health (CVS), thanks to strength in its PBM business.

Here's Why Chemed (CHE) Should Remain in Your Portfolio Now

by Zacks Equity Research

Investors' trust in Chemed (CHE) continues to be high, banking on its sturdy segmental performance.